CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector. The Health Care Select Sector SPDR (XLV) has outperformed the S&P 500 in the past six months.
On too if this, healthcare is a market sector that could realize growth even though there may be a global slowdown or an economic breakdown. The main reason is that these factors generally do not have an impact on health issues or diseases. For this reason, it might be a good idea to pay attention to some names within this sector.
Big news from several companies within the industry has 4 healthcare stocks on watch Tuesday including Premier Health Group, Inc. (PHGRF) (PHGI), Aethlon Medical, Inc. (AEMD), Precipio, Inc. (PRPO), and Arsanis, Inc. (ASNS).
This move could prove to be and exciting one for Premier. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025. With this in mind, the company said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19.
Premier Health Group, Inc. (PHGRF) (PHGI) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. Furthermore, the Company is actively recruiting additional physicians for its existing clinics and a cannabis-focused physician that is licensed in Canada.
Premier Health Group, Inc. (PHGRF) (PHGI)'s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.
"With over 110,000 active patients in our clinic ecosystem it is important that we provide them with the best possible information that allows them to make informed decisions about their personal and family's health. Providing our family physicians with the appropriate tools and knowledge to prescribe cannabis or with the ability to refer patients to a specialist within our clinics is a key outcome of this initiative," said Dr. Essam Hamza, CEO of Premier.
Aethlon Medical, Inc. (AEMD) is focused on addressing unmet needs in global health. The Aethlon Hemopurifier® is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.
Tuesday morning the company announced that it has received a "Breakthrough Device" designation from the U.S. Food and Drug Administration (FDA) to support the advancement of the Aethlon Hemopurifier® for the treatment of cancer. The Aethlon Hemopurifier is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and life-threatening viruses.
"We are honored to receive this breakthrough designation in oncology as it establishes an opportunity to expand the market for our Hemopurifier and advance our vision for addressing a significant unmet need in cancer care," stated Aethlon Medical founder and CEO, Jim Joyce. "By reducing the presence of tumor-derived exosomes from the circulatory system of cancer patients, we believe our Hemopurifier can improve the benefit of existing cancer treatment regimens and emerging immuno-oncology drugs. Thus providing a rationale for potential partnering opportunities."
Shares of Aethlon have traded as high as $2.30 during pre-market hours on Tuesday.
Precipio, Inc. (PRPO) has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide.
Tuesday morning the company announced that its ICE COLD-PCR™ (ICP) technology has been selected for a screening study to identify clinically actionable mutations in non-small cell lung cancer (NSCLC) at the University of Cincinnati Medical Center. The study will focus on utilizing ICP mutation enrichment along with High Resolution Melt Analysis (HRM) screening technology to screen actionable mutations in epidermal growth factor receptor (EGFR) for NSCLC.
"Our goal is to use Precipio's ICP technology to quickly identify patients who are negative for EGFR mutations and then move only those patients who are positive to downstream molecular testing with RT-PCR," said Dr. Kurt B. Hodges, Associate Professor of Pathology and Laboratory Medicine and Primary Investigator of the study. "Identifying patients with clinically actionable mutations in NSCLC as quickly as possible and then monitoring these patients for responses to commonly prescribed NSCLC therapeutics is critical for precision medicine."
Shares of Precipio have traded between lows of $0.25 and highs of $0.3299 during the last 30 days.
Arsanis, Inc. (ASNS) is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. This morning the company and privately-held X4 Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4's lead product candidate, X4P-001, and the advancement of X4's pipeline of treatments for rare diseases of the immune system and rare cancers.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer.
This morning, shares of Arsanis have traded as high as $1.70 during pre-market hours.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.